Does Fallon Community Health Plan (FCHP) Cover Prolia?

What Is Prolia and Why Do Doctors Prescribe It?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), the protein that drives osteoclast-mediated bone resorption. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later expanded that label to include bone loss in men receiving androgen-deprivation therapy for prostate cancer, bone loss in women receiving aromatase inhibitors for breast cancer, and glucocorticoid-induced osteoporosis [1].

The landmark FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months (P<0.001 for all three endpoints) [2]. Those numbers explain why endocrinologists and rheumatologists reach for Prolia when bisphosphonates have failed, are contraindicated, or when a patient cannot reliably take a weekly oral pill.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines position denosumab as a first-line option for patients with very high fracture risk, defined as a FRAX 10-year major osteoporotic fracture probability above 20% or a prior hip or vertebral fracture [3]. Because Prolia is a branded biologic with a list price near $1,400 per dose, most commercial and Medicare Advantage plans, including FCHP, place it behind a utilization-management gate.

Clinically, one detail separates Prolia from bisphosphonates: abrupt discontinuation causes a rebound increase in bone turnover markers and a documented risk of multiple vertebral fractures within 12 to 18 months of the missed injection [4]. That makes coverage continuity a genuine patient-safety issue, not just a financial one.

How FCHP Structures Its Pharmacy and Medical Benefits

FCHP offers several plan lines including commercial HMO products, a Medicare Advantage plan (Fallon Senior Plan), and MassHealth-contracted Medicaid products. Whether Prolia falls under the pharmacy benefit or the medical benefit matters because the cost-sharing rules differ substantially between the two.

In most commercial HMO designs, a drug administered in a physician's office or infusion center is billed under the medical benefit using a procedure code (J0897 for denosumab). Under the medical benefit, the member typically pays a specialist office-visit copay plus a percentage coinsurance on the drug itself. In Medicare Advantage plans, denosumab administered in a physician office is usually covered under Part B rules, meaning 20% coinsurance after the Part B deductible once the plan's cost-sharing structure is applied [5].

If a member self-injects or obtains Prolia through a specialty pharmacy for home administration (less common), the claim runs through the pharmacy benefit and is subject to the plan's specialty drug tier copay, which in most FCHP commercial plans sits at the highest tier with the largest member cost share.

The National Comprehensive Cancer Network (NCCN) and the Endocrine Society both publish clinical guidance that payers use when building coverage policies [6]. FCHP's medical policies reference clinical evidence and professional society guidelines when setting prior authorization criteria, so understanding those guidelines helps clinicians write stronger authorization letters.

Prior Authorization: What FCHP Typically Requires

Prior authorization for Prolia at FCHP is standard practice. The authorization request generally must include the following documentation.

A dual-energy X-ray absorptiometry (DXA) scan result showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, or a T-score at or below -1.0 combined with a documented fragility fracture [7]. The DXA must typically be performed within the prior 24 months. The National Osteoporosis Foundation recommends DXA screening for all women 65 and older and for younger postmenopausal women with risk factors, a threshold that aligns with the U.S. Preventive Services Task Force (USPSTF) recommendation [8].

Step therapy documentation showing that the member has tried and failed, or has a documented contraindication to, at least one bisphosphonate. Alendronate 70 mg weekly is the most common required first-line agent. Failure criteria accepted by most plans include gastrointestinal intolerance documented in clinical notes, a creatinine clearance below 35 mL/min (which contraindicates most oral bisphosphonates), or an incident hip or vertebral fracture that occurred while on bisphosphonate therapy [9].

A prescribing physician attestation that the patient's diagnosis meets the FDA-approved label or a recognized off-label use supported by compendia listing (e.g., the American Hospital Formulary Service Drug Information or the NCCN Drugs and Biologics Compendium) [1].

Labs showing serum calcium within normal limits are sometimes required because hypocalcemia is the most common serious adverse effect of denosumab and is listed prominently in the FDA prescribing information [1].

Once submitted, Massachusetts state law requires health plans to respond to standard prior authorization requests within a defined timeframe. FCHP, as a Massachusetts-licensed carrier, must comply with the state's insurance regulations governing timely review. Urgent requests require a faster turnaround than routine requests.

Step Therapy and When FCHP May Waive It

Step therapy is the requirement that a member try a lower-cost drug before the plan will cover a more expensive alternative. For osteoporosis, FCHP commonly requires a trial of an oral bisphosphonate before approving Prolia. Alendronate (generic, roughly $15 to $30 per month) is the most frequently required agent, consistent with cost-effectiveness analyses showing it reduces vertebral fracture risk by approximately 45 to 50% at far lower cost [10].

Step therapy can be waived when a contraindication to bisphosphonates is clearly documented. Renal impairment is the most frequently invoked contraindication. Oral bisphosphonates carry an FDA label warning against use when creatinine clearance falls below 35 mL/min (for alendronate and risedronate) or below 30 mL/min (for ibandronate) [11]. A documented eGFR in the record removes the step therapy requirement in most plans.

Esophageal disease, including Barrett esophagus, active esophagitis, or an inability to sit upright for 30 minutes after swallowing a tablet, is another accepted contraindication. Atypical femoral fractures or osteonecrosis of the jaw attributed to prior bisphosphonate use are also grounds for bypass [12].

For patients on glucocorticoid therapy of 7.5 mg prednisone equivalent per day or more for 6 months or longer, the American College of Rheumatology 2022 guidelines recommend denosumab as a first-line agent rather than requiring bisphosphonate failure first, which can support a step therapy waiver argument in that specific population [13].

How to Request a Prior Authorization for Prolia Through FCHP

The prescribing clinician, usually the ordering endocrinologist, rheumatologist, or primary care physician, initiates the prior authorization request. The process typically moves through these steps.

First, the office submits a prior authorization form to FCHP along with the supporting clinical documentation described in the previous section. Many practices use the CoverMyMeds platform or a similar electronic prior authorization tool to submit directly to FCHP's utilization management department.

Second, FCHP's clinical reviewers assess the submission against their coverage criteria. If documentation is complete and meets the threshold, approval is issued. If documentation is incomplete, the plan issues a request for additional information rather than an immediate denial.

Third, if FCHP issues a denial, the member and prescriber receive a written Explanation of Benefits or Adverse Benefit Determination letter stating the specific reason for denial and the member's appeal rights under Massachusetts law and, for Medicare Advantage members, under federal Medicare regulations [14].

The HealthRX clinical team uses the following documentation checklist when helping patients prepare a Prolia prior authorization packet for any commercial or Medicare Advantage plan:

1. DXA report with T-scores at all three sites (lumbar spine, femoral neck, total hip) dated within 24 months.
2. FRAX score printout from the WHO Fracture Risk Assessment Tool, calculated with BMD input.
3. Prescriber letter stating the specific FDA-approved indication and the patient's fracture history.
4. Lab results: serum calcium, phosphorus, 25-hydroxyvitamin D, and creatinine with eGFR, all within 90 days.
5. Documentation of prior bisphosphonate trial (dates, dose, duration, reason for discontinuation) or a clearly worded contraindication statement with supporting clinical evidence.
6. Any relevant imaging reports showing incident fractures.

What Happens When FCHP Denies Prolia Coverage

A denial is not the end of the road. Massachusetts law and, for Medicare Advantage members, federal law give members defined appeal rights. The typical appeals pathway has three to four stages.

Internal appeal. The member or prescriber submits a written appeal to FCHP's appeals department within the timeframe stated in the denial letter (commonly 60 to 180 days). The appeal should include any additional clinical documentation not submitted with the original request, a letter from the prescribing physician explaining why Prolia is medically necessary, and citations to relevant clinical guidelines [15]. The FREEDOM trial data [2] and AACE guidelines [3] are particularly useful supporting references.

External appeal. If the internal appeal is denied, Massachusetts members can request an independent external review through the Massachusetts Office of Patient Protection. External reviewers are board-certified clinicians with no affiliation to FCHP, and their decisions are binding on the plan [16].

Medicare Advantage specific pathway. For Fallon Senior Plan Medicare Advantage members, the appeals hierarchy follows the CMS-defined Medicare appeals process: redetermination by the plan, reconsideration by a Qualified Independent Contractor (QIC), ALJ hearing, Medicare Appeals Council review, and federal district court review. A coverage determination that a drug is "not medically necessary" for a Medicare beneficiary can also trigger expedited review if the prescriber certifies that waiting for the standard timeline would seriously jeopardize the member's health [14].

National data from the Kaiser Family Foundation show that about 60% of all prior authorization denials across Medicare Advantage plans are overturned when formally appealed, which underlines the value of pursuing the process rather than abandoning it [17].

Cost-Sharing: What FCHP Members Pay Out of Pocket

Actual cost-sharing depends on the member's specific FCHP plan, the benefit category under which Prolia is processed (medical vs. pharmacy), and whether the member has met the plan's annual deductible.

Under the medical benefit, Prolia administered in a physician office is billed as a procedure. Members on FCHP commercial HMO plans commonly pay a specialist office-visit copay, typically $40 to $60, plus a coinsurance percentage on the drug charge itself. At a list price of approximately $1,400 per dose and a 20% coinsurance rate, the member's drug cost alone could approach $280 per injection before any manufacturer assistance.

Amgen, the manufacturer of Prolia, operates a patient assistance program called the Amgen Safety Net Foundation for patients who are uninsured or underinsured, as well as a copay card program (Amgen Assist) for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per dose, subject to eligibility rules and annual cap limits [18]. Amgen copay cards cannot be used by Medicare beneficiaries under federal anti-kickback rules, so Fallon Senior Plan members need to ask specifically about the Amgen Safety Net Foundation income-based assistance instead.

For Medicare Advantage members in the Fallon Senior Plan, Prolia administered in a physician office falls under Part B cost-sharing rules. After the Part B deductible (set by CMS at $240 for 2024), members typically pay 20% coinsurance. Plans vary in whether they reduce that 20% through supplemental benefits. Members who qualify for the Medicare Extra Help (Low Income Subsidy) program may pay substantially less [5].

Prolia vs. Other Osteoporosis Drugs: Coverage Likelihood Comparison

Understanding how FCHP tiers competing drugs helps clinicians and patients plan alternative strategies when Prolia authorization is delayed.

Oral bisphosphonates (alendronate, risedronate, ibandronate) are generic, appear on most formularies at Tier 1 or Tier 2, and require no prior authorization in the vast majority of plan designs. A 90-day supply of generic alendronate 70 mg weekly costs under $20 at major pharmacies.

Zoledronic acid (Reclast, 5 mg IV annually) is administered in an infusion setting and processed under the medical benefit. It is usually covered with prior authorization criteria similar to, but sometimes slightly less stringent than, those for Prolia. The HORIZON Key Fracture Trial (N=7,765) showed zoledronic acid reduced vertebral fracture risk by 70% at 3 years [19], making it a clinically comparable alternative that plans sometimes accept more readily than Prolia.

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents indicated for patients at very high fracture risk. Both carry list prices above $25,000 per year and face the strictest prior authorization criteria, generally limited to patients with two or more prior fragility fractures or T-scores below -3.0 after bisphosphonate failure [20].

Romosozumab (Evenity), a sclerostin inhibitor approved by the FDA in April 2019, carries a boxed warning for cardiovascular risk and is similarly restricted to very high-risk patients with prior fracture and no significant cardiovascular history [21].

Against that backdrop, Prolia occupies a middle tier: clinically preferred over oral bisphosphonates in specific populations, easier to authorize than anabolic agents, and increasingly well-supported by long-term extension data from the FREEDOM Extension study, which followed patients for up to 10 years [22].

Special Populations: FCHP Coverage Nuances

Men with osteoporosis. The FDA approved Prolia for osteoporosis in men at high fracture risk in September 2012 [1]. FCHP commercial plans generally extend coverage to men using the same T-score and step therapy criteria as for postmenopausal women, but the prescriber must specify the male osteoporosis indication explicitly on the authorization form. The ADAMO trial (N=242) demonstrated significant increases in lumbar spine BMD in men receiving denosumab compared with placebo [23], supporting the medical necessity argument.

Cancer-related bone loss. Prolia is FDA-approved for bone loss in men receiving androgen-deprivation therapy (ADT) for nonmetastatic prostate cancer and in women receiving adjuvant aromatase inhibitor therapy for breast cancer. In these indications, prior authorization criteria sometimes differ from the postmenopausal osteoporosis pathway. The prescribing oncologist should submit documentation of the underlying malignancy, the hormonal therapy being used, and the resulting bone density change [24].

Glucocorticoid-induced osteoporosis. Patients on long-term glucocorticoid therapy represent a distinct clinical population. The 2022 American College of Rheumatology guidelines specifically recommend denosumab for high-risk patients in this category, a recommendation that can support a direct-to-Prolia authorization without bisphosphonate step therapy [13].

Premenopausal women. This is an off-label use and one of the harder authorizations to obtain. FCHP may require compendia support and a specialist attestation. Prolia is not FDA-approved for premenopausal women and carries a fetal toxicity warning.

If Your FCHP Prolia Coverage Lapses: Why This Matters Clinically

Missing or delaying a Prolia dose carries a risk that does not apply to most other osteoporosis medications. A 2017 case series and subsequent pharmacovigilance reports documented clusters of multiple vertebral fractures occurring within 7 to 17 months after the last denosumab injection in patients who discontinued treatment [4]. The European Medicines Agency added a label warning about this rebound phenomenon, and the FDA updated the Prolia prescribing information to include guidance on transitioning patients to an alternative antiresorptive agent when Prolia must be stopped [1].

For members facing a coverage gap due to a pending prior authorization, an appeal, or a plan transition, the prescribing physician should consider bridging therapy with a bisphosphonate or documenting a plan for the next injection as part of the appeal's urgency argument. The Endocrine Society clinical practice guideline on osteoporosis in postmenopausal women recommends reassessing fracture risk every 1 to 2 years and explicitly notes the rebound risk associated with denosumab discontinuation [6].

Navigating FCHP's Member Resources

FCHP provides a member portal at fchp.org where members can check formulary status, submit prior authorization requests electronically, and review appeal forms. The plan's pharmacy department can be reached directly to confirm whether a specific NDC for Prolia is on the current formulary and what the applicable cost-sharing tier is for the member's specific plan year.

Members can also contact a HealthRX care navigator to help compile prior authorization documentation, draft a medical necessity letter, or identify manufacturer patient assistance programs. Having a complete documentation packet assembled before the prescriber submits the authorization reduces the likelihood of a request-for-information delay and shortens the overall approval timeline.

The CDC reports that approximately 10 million Americans have osteoporosis and another 44 million have low bone density, placing them at elevated fracture risk [25]. Vertebral and hip fractures carry substantial morbidity, with hip fractures in particular associated with a 20 to 24% one-year mortality rate in older adults [26]. That clinical weight supports the argument, in any appeal, that Prolia coverage is not a luxury but a medically indicated intervention with a defined evidence base.